Coherus BioSciences Inc. (CHRS) and VIVUS Inc. (NASDAQ:VVUS) Comparison side by side

Coherus BioSciences Inc. (NASDAQ:CHRS) and VIVUS Inc. (NASDAQ:VVUS), are influenced by contrast since they are both players in the Biotechnology. These factors are particularly influence the analyst recommendations, institutional ownership, profitability, risk, dividends, earnings and valuation of the two firms.

Earnings and Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Coherus BioSciences Inc. N/A 0.00 209.34M -3.13 0.00
VIVUS Inc. 65.06M 0.58 36.95M -3.98 0.00

Table 1 shows gross revenue, earnings per share and valuation of the two companies.


Table 2 represents Coherus BioSciences Inc. (NASDAQ:CHRS) and VIVUS Inc. (NASDAQ:VVUS)’s return on equity, net margins and return on assets.

Net Margins Return on Equity Return on Assets
Coherus BioSciences Inc. 0.00% -742.4% -126.3%
VIVUS Inc. -56.79% 0% 0%

Volatility and Risk

Coherus BioSciences Inc.’s current beta is 3.63 and it happens to be 263.00% more volatile than S&P 500. Competitively, VIVUS Inc. is 123.00% more volatile than S&P 500, because of the 2.23 beta.


The Current Ratio and Quick Ratio of Coherus BioSciences Inc. are 5.3 and 5.3 respectively. Its competitor VIVUS Inc.’s Current Ratio is 3.9 and its Quick Ratio is 3.3. Coherus BioSciences Inc. can pay off short and long-term obligations better than VIVUS Inc.

Analyst Recommendations

In next table is delivered Coherus BioSciences Inc. and VIVUS Inc.’s ratings and recommendations.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Coherus BioSciences Inc. 0 0 2 3.00
VIVUS Inc. 0 0 0 0.00

Coherus BioSciences Inc. has an average target price of $25, and a 69.15% upside potential.

Insider and Institutional Ownership

Institutional investors owned 98.8% of Coherus BioSciences Inc. shares and 17.7% of VIVUS Inc. shares. About 0.4% of Coherus BioSciences Inc.’s share are owned by insiders. Comparatively, 0.7% are VIVUS Inc.’s share owned by insiders.


In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Coherus BioSciences Inc. 1.49% 11.66% 36.64% -25.41% 53.37% 66.08%
VIVUS Inc. -8.8% -4.6% 56.7% -23.5% 7.24% 104.48%

For the past year Coherus BioSciences Inc.’s stock price has smaller growth than VIVUS Inc.


VIVUS Inc. beats Coherus BioSciences Inc. on 6 of the 10 factors.

Coherus BioSciences, Inc., a late-stage clinical biologics platform company, focuses on developing and commercializing biosimilar products worldwide. The company’s product candidates include CHS-1701, a pegfilgrastim biosimilar candidate, which is used for the treatment of febrile neutropenia; CHS-0214, an etanercept biosimilar candidate, which is in various phases of clinical trials for the treatment of ankylosing spondylitis, juvenile idiopathic arthritis, psoriatic arthritis, rheumatoid arthritis, and psoriasis; and CHS-5217, a bevacizumab biosimilar candidate, which is in preclinical stage for the treatment of metastatic colorectal cancer, non–small cell lung cancer, metastatic kidney cancer, advanced cervical cancer, platinum-resistant ovarian cancer, and recurrent glioblastoma. Its product candidates also comprise CHS-1420, an adalimumab biosimilar candidate, which is in various phases of clinical trials to treat ankylosing spondylitis, Behçet's Disease, Crohn’s Disease, juvenile idiopathic arthritis, psoriasis, psoriatic arthritis, rheumatoid arthritis, and ulcerative colitis; and CHS-3351, a ranibizumab biosimilar candidate, which is in preclinical stage for the treatment of neovascular (wet) age-related macular, degeneration, macular edema following retinal vein occlusion, diabetic macular edema, and diabetic retinopathy. Coherus Biosciences, Inc. has license agreement with Daiichi Sankyo Company, Limited; Baxalta Incorporated, Baxalta US Inc., and Baxalta GmbH; Genentech, Inc.; and Selexis SA. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus Biosciences, Inc. in April 2012. Coherus Biosciences, Inc. was founded in 2010 and is headquartered in Redwood City, California.

VIVUS, Inc., a biopharmaceutical company, develops and commercializes therapies to address unmet medical needs in the United States and the European Union. The company offers Qsymia for the treatment of obesity as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index of 30 or greater, or 27 or greater in the presence of at least one weight-related comorbidity, such as hypertension, type 2 diabetes mellitus or high cholesterol; and STENDRA, an oral phosphodiesterase type 5 inhibitor for the treatment of erectile dysfunction. It is also developing Qsymia, which has completed Phase II studies for the treatment of obstructive sleep apnea and diabetes, as well as for other obesity-related diseases, including nonalcoholic steatohepatitis, nonalcoholic fatty liver disease, hyperlipidemia, and hypertension. In addition, the company is developing Tacrolimus, which has completed Phase IIa studies for the treatment of pulmonary arterial hypertension. It has development, license and clinical trial, and commercial supply agreement with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of avanafil, a PDE5 inhibitor compound for the oral and local treatment of male and female sexual dysfunction. The company also has license and commercialization agreements with Berlin-Chemie AG and Auxilium Pharmaceuticals, Inc. to commercialize and promote STENDRA; and with Sanofi Winthrop Industrie to commercialize and promote avanafil. VIVUS, Inc. was founded in 1991 and is headquartered in Campbell, California.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.